BR0208275A - Composições farmacêuticas para tratamento de arteriosclerose - Google Patents
Composições farmacêuticas para tratamento de arterioscleroseInfo
- Publication number
- BR0208275A BR0208275A BR0208275-6A BR0208275A BR0208275A BR 0208275 A BR0208275 A BR 0208275A BR 0208275 A BR0208275 A BR 0208275A BR 0208275 A BR0208275 A BR 0208275A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- treating atherosclerosis
- treating
- group
- arteriosclerosis
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 2
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 2
- 102000004895 Lipoproteins Human genes 0.000 abstract 1
- 108090001030 Lipoproteins Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000023589 ischemic disease Diseases 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Indole Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001078569 | 2001-03-19 | ||
| JP2001401289 | 2001-12-28 | ||
| PCT/JP2002/002585 WO2002074342A1 (en) | 2001-03-19 | 2002-03-19 | Remedies for arteriosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0208275A true BR0208275A (pt) | 2004-04-13 |
Family
ID=26611547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0208275-6A BR0208275A (pt) | 2001-03-19 | 2002-03-19 | Composições farmacêuticas para tratamento de arteriosclerose |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20040248898A1 (enExample) |
| EP (2) | EP2044958A3 (enExample) |
| JP (1) | JP4499361B2 (enExample) |
| KR (1) | KR100908968B1 (enExample) |
| CN (1) | CN1553814B (enExample) |
| AT (1) | ATE428425T1 (enExample) |
| BR (1) | BR0208275A (enExample) |
| CA (1) | CA2441110C (enExample) |
| DE (1) | DE60231969D1 (enExample) |
| ES (1) | ES2324766T3 (enExample) |
| MX (1) | MXPA03008440A (enExample) |
| PT (1) | PT1378246E (enExample) |
| TW (1) | TWI314457B (enExample) |
| WO (1) | WO2002074342A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2002000621A1 (ja) * | 2000-06-29 | 2004-04-22 | 塩野義製薬株式会社 | Ｘ型ｓＰＬＡ２阻害作用を有する化合物 |
| US20050244367A1 (en) * | 2004-05-03 | 2005-11-03 | Ilypsa, Inc. | Phospholipase inhibitors localized in the gastrointestinal lumen |
| KR20070091607A (ko) | 2004-10-12 | 2007-09-11 | 디코드 제네틱스, 아이엔씨. | 폐쇄성 동맥 질환용의 설폰아미드 주변 치환된바이사이클릭 화합물 |
| US8329913B2 (en) | 2004-10-29 | 2012-12-11 | Zeria Pharmaceutical Co., Ltd. | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof |
| US7666898B2 (en) | 2005-11-03 | 2010-02-23 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors |
| CA2627352A1 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors |
| EP2027117A2 (en) | 2006-05-16 | 2009-02-25 | Decode Genetics EHF | Process for preparing 7-(acryloyl)-indoles |
| EP2154958A4 (en) * | 2007-05-03 | 2011-05-04 | Anthera Pharmaceuticals Inc | TREATMENT OF HEART CIRCULATION DISEASES AND DYSLIPIDEMIA WITH INHIBITORS OF SECRETARY PHOSPHOLIPASE A2 (SPLA2) AND SPLA2 HEMMER COMBINATION THERAPIES |
| US8048880B2 (en) * | 2007-05-03 | 2011-11-01 | Anthera Pharmaceuticals, Inc. | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies |
| US20090062369A1 (en) * | 2007-08-31 | 2009-03-05 | Joaquim Trias | Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels |
| WO2010038104A1 (en) * | 2008-10-03 | 2010-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event. |
| NZ720946A (en) | 2009-04-29 | 2017-09-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| KR101037404B1 (ko) * | 2010-12-07 | 2011-05-30 | 박철형 | 가변설치가 가능한 압출본체에 의한 천장용 엘이디 조명등 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL109311A0 (en) | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| IL109309A (en) * | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| EP0658205B1 (en) * | 1993-06-25 | 2000-03-15 | Smithkline Beecham Plc | Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy |
| US5498608A (en) * | 1994-01-07 | 1996-03-12 | Salix Pharmaceuticals | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents |
| JP3109974B2 (ja) | 1994-04-01 | 2000-11-20 | イーライ・リリー・アンド・カンパニー | １Ｈ−インドール−３−グリオキシルアミドｓＰＬＡ２阻害剤 |
| US6214876B1 (en) | 1994-07-21 | 2001-04-10 | Eli Lilly And Company | Indene-1-acetamide sPLA2 inhibitors |
| BR9508298A (pt) | 1994-07-21 | 1998-11-03 | Shionogi & Co | Inibidores de indolizina de spla2 |
| US5641800A (en) | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
| US6160175A (en) | 1995-12-13 | 2000-12-12 | Eli Lilly And Company | Naphthyl acetamides as sPLA2 inhibitors |
| WO1997021716A1 (en) | 1995-12-13 | 1997-06-19 | Eli Lilly And Company | NAPHTHYL GLYOXAMIDES AS sPLA2 INHIBITORS |
| KR20000049210A (ko) * | 1996-10-30 | 2000-07-25 | 피터 지. 스트링거 | 치환된 트리시클릭류 |
| US6353128B1 (en) | 1996-12-03 | 2002-03-05 | Eli Lilly And Company | Phenyl acetamides as sPLA2 inhibitors |
| US5916922A (en) | 1996-12-03 | 1999-06-29 | Eli Lilly And Company | Phenyl glyoxamides as SPLA2 inhibitors |
| ID18983A (id) | 1996-12-04 | 1998-05-28 | Lilly Co Eli | Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia |
| US5919774A (en) | 1996-12-10 | 1999-07-06 | Eli Lilly And Company | Pyrroles as sPLA2 inhibitors |
| HUP0102981A3 (en) * | 1998-03-31 | 2002-10-28 | Shionogi & Co | Pyrrolo[1,2-a]pyrazine derivatives and pharmaceutical compositions thereof |
| KR20010034881A (ko) * | 1998-05-21 | 2001-04-25 | 시오노 요시히코 | ｓＰＬＡ2 억제 효과를 갖는 피롤로[1,2-ｂ]피리다진 유도체 |
| ATE329619T1 (de) * | 1998-10-14 | 2006-07-15 | Shionogi & Co | Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden |
| US6756376B1 (en) * | 1999-11-15 | 2004-06-29 | Shionogi & Co., Ltd. | Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities |
| JPWO2002000621A1 (ja) * | 2000-06-29 | 2004-04-22 | 塩野義製薬株式会社 | Ｘ型ｓＰＬＡ２阻害作用を有する化合物 |
-
2002
- 2002-03-18 TW TW091105096A patent/TWI314457B/zh not_active IP Right Cessation
- 2002-03-19 BR BR0208275-6A patent/BR0208275A/pt not_active Application Discontinuation
- 2002-03-19 ES ES02705327T patent/ES2324766T3/es not_active Expired - Lifetime
- 2002-03-19 US US10/472,234 patent/US20040248898A1/en not_active Abandoned
- 2002-03-19 MX MXPA03008440A patent/MXPA03008440A/es active IP Right Grant
- 2002-03-19 CN CN028095529A patent/CN1553814B/zh not_active Expired - Fee Related
- 2002-03-19 WO PCT/JP2002/002585 patent/WO2002074342A1/ja not_active Ceased
- 2002-03-19 CA CA2441110A patent/CA2441110C/en not_active Expired - Fee Related
- 2002-03-19 KR KR1020037012268A patent/KR100908968B1/ko not_active Expired - Fee Related
- 2002-03-19 AT AT02705327T patent/ATE428425T1/de not_active IP Right Cessation
- 2002-03-19 EP EP08021793A patent/EP2044958A3/en not_active Withdrawn
- 2002-03-19 EP EP02705327A patent/EP1378246B1/en not_active Expired - Lifetime
- 2002-03-19 JP JP2002573049A patent/JP4499361B2/ja not_active Expired - Fee Related
- 2002-03-19 PT PT02705327T patent/PT1378246E/pt unknown
- 2002-03-19 DE DE60231969T patent/DE60231969D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1553814A (zh) | 2004-12-08 |
| ATE428425T1 (de) | 2009-05-15 |
| MXPA03008440A (es) | 2004-01-29 |
| CA2441110A1 (en) | 2002-09-26 |
| TWI314457B (enExample) | 2009-09-11 |
| EP1378246A1 (en) | 2004-01-07 |
| CA2441110C (en) | 2010-10-12 |
| JP4499361B2 (ja) | 2010-07-07 |
| EP2044958A3 (en) | 2009-07-08 |
| PT1378246E (pt) | 2009-05-22 |
| DE60231969D1 (de) | 2009-05-28 |
| JPWO2002074342A1 (ja) | 2004-07-08 |
| ES2324766T3 (es) | 2009-08-14 |
| WO2002074342A1 (en) | 2002-09-26 |
| CN1553814B (zh) | 2010-05-26 |
| KR100908968B1 (ko) | 2009-07-22 |
| EP1378246B1 (en) | 2009-04-15 |
| EP1378246A4 (en) | 2004-07-07 |
| KR20030085026A (ko) | 2003-11-01 |
| US20040248898A1 (en) | 2004-12-09 |
| EP2044958A2 (en) | 2009-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT896533E (pt) | Pentafluorobenzenosulfonamidas e analogos | |
| BR0113989A (pt) | Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos | |
| IS6859A (is) | Kristölluð form atorvastatíns | |
| PT989851E (pt) | Formulacao auto-emulsionante para compostos lipofilicos acidicos | |
| BR0209468A (pt) | Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar | |
| EE200300329A (et) | Meetod peroraalselt manustatavate epotiloonide biosaadavuse suurendamiseks ning selles kasutatav komplekt, ravimkoostis ja farmatseutiline ravimvorm | |
| BR9814327A (pt) | Compostos de tiouréia e benzamida, composições e pro-cessos para tratamento ou prevenção de doenças infla-matórias e arteriosclerose | |
| DK0639577T3 (da) | Phosphonooxymethyl- eller methylthiomethylestere af taxanderivater som antitumormidler | |
| PT911333E (pt) | Derivados de pirazolo¬4,3-d|pirimidina e composicoes farmaceuticas que os contenham | |
| NO2011026I2 (no) | Eribulin eller et farmasøytisk akseptabelt salt derav | |
| DE60131160D1 (de) | Caspase-inhibitoren und ihre verwendungen | |
| MXPA03008440A (es) | Composiciones farmaceuticas para tratamiento de arteriosclerosis. | |
| BR0212386A (pt) | Composto, formulação farmacêutica, e, uso de um composto | |
| SE0301446D0 (sv) | New Compounds | |
| IT1312115B1 (it) | Composti amorfi e relative composizioni farmaceutiche | |
| DE60129442D1 (de) | Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten | |
| CY1106376T1 (el) | Δικυκλικα παραγωγα των αμινο-πυραζινονων, μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα πepιεχουν | |
| CY1105939T1 (el) | Παραγωγα βενζοθειαζινης και βενζοθεαδιαζινης, μεθοδος παρασκευης αυτων και φαρμακευτικες συνθεσεις οι οποιες τα πepιεχουν | |
| BRPI0414186A (pt) | compostos, métodos de antagonizar a atividade de cetp, de tratar ou prevenir uma doença, de diminuir o colesterol ldl plasmático em um mamìmero, de tratar e/ou prevenir seqüelas patológicas, formulação farmacêutica, e, uso de um composto | |
| BRPI0517065A (pt) | derivado de ácido carboxìlico que contém anel de tiazol e uso farmacêutico deste | |
| BRPI0408423A (pt) | composições farmacêuticas compreendendo uma combinação de rapamicina ou seus derivados e pimecrolimus para o tratamento de doenças mediadas imunologicamente e por inflamação | |
| EA200301101A1 (ru) | Производные пиперазина и их применение в качестве ингибиторов pde4 | |
| ES2189080T3 (es) | Derivados de creatina para el asma. | |
| DK0937708T3 (da) | Sulfonamidderivater | |
| BRPI0206922B8 (pt) | composto de fragrância, composição de fragrância contendo o mesmo, e método para preparação de um composto de fragrância |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |